BACKGROUND: Bet v 1 and homologous proteins represent major allergens for almost 95% of patients allergic to tree pollen and approximately 70% of those allergic to fruits and vegetables. As yet, no continuous (sequential) IgE epitopes have been determined for Bet v 1, and evidence has accumulated that Bet v 1 IgE epitopes belong to the conformational (discontinuous) type. OBJECTIVE: A panel of 85 mouse monoclonal anti-Bet v 1 antibodies was raised as a tool with which to study the interaction of human IgE antibodies with Bet v 1. METHODS: The epitopes of selected monoclonal antibodies (mAbs) were characterized by mapping with synthetic overlapping peptides and by cross-competition experiments. Cross-reactivity of Bet v 1-specific mAbs with tree and plant food allergens was investigated by Western blotting. The influence of Bet v 1-specific mAbs on the IgE-Bet v 1 interaction was studied by competition assays with immobilized purified recombinant Bet v 1 and by basophil histamine release experiments. RESULTS: Antibodies that increased the IgE binding to Bet v 1 up to fivefold could be defined, whereas others inhibited IgE binding to Bet v 1 up to 99% and competed with the Bet v 1-induced histamine release from patients' basophils. CONCLUSION: The activity of the enhancing antibodies is interpreted as a stabilization of Bet v 1 states/IgE epitopes, which are either more accessible for certain IgE antibodies or are recognized with higher affinity. Those mAbs that competed with the Bet v 1-IgE interaction, if humanized or produced as recombinant antibody fragments, might be considered as potential tools for local allergy therapy.
BACKGROUND:Bet v 1 and homologous proteins represent major allergens for almost 95% of patients allergic to tree pollen and approximately 70% of those allergic to fruits and vegetables. As yet, no continuous (sequential) IgE epitopes have been determined for Bet v 1, and evidence has accumulated that Bet v 1 IgE epitopes belong to the conformational (discontinuous) type. OBJECTIVE: A panel of 85 mouse monoclonal anti-Bet v 1 antibodies was raised as a tool with which to study the interaction of human IgE antibodies with Bet v 1. METHODS: The epitopes of selected monoclonal antibodies (mAbs) were characterized by mapping with synthetic overlapping peptides and by cross-competition experiments. Cross-reactivity of Bet v 1-specific mAbs with tree and plant food allergens was investigated by Western blotting. The influence of Bet v 1-specific mAbs on the IgE-Bet v 1 interaction was studied by competition assays with immobilized purified recombinant Bet v 1 and by basophil histamine release experiments. RESULTS: Antibodies that increased the IgE binding to Bet v 1 up to fivefold could be defined, whereas others inhibited IgE binding to Bet v 1 up to 99% and competed with the Bet v 1-induced histamine release from patients' basophils. CONCLUSION: The activity of the enhancing antibodies is interpreted as a stabilization of Bet v 1 states/IgE epitopes, which are either more accessible for certain IgE antibodies or are recognized with higher affinity. Those mAbs that competed with the Bet v 1-IgE interaction, if humanized or produced as recombinant antibody fragments, might be considered as potential tools for local allergy therapy.
Authors: Randall M Goldblum; Bo Ning; Barbara M Judy; Luis Marcelo F Holthauzen; Julius van Bavel; Atsushi Kamijo; Terumi Midoro-Horiuti Journal: Mol Immunol Date: 2016-05-09 Impact factor: 4.407
Authors: Sylvia Laffer; Said Hamdi; Christian Lupinek; Wolfgang R Sperr; Peter Valent; Petra Verdino; Walter Keller; Monika Grote; Karin Hoffmann-Sommergruber; Otto Scheiner; Dietrich Kraft; Marc Rideau; Rudolf Valenta Journal: Biochem J Date: 2003-07-01 Impact factor: 3.857
Authors: Hanna Berkner; Christian Seutter von Loetzen; Maximilian Hartl; Stefanie Randow; Michaela Gubesch; Lothar Vogel; Felix Husslik; Andreas Reuter; Jonas Lidholm; Barbara Ballmer-Weber; Stefan Vieths; Paul Rösch; Dirk Schiller Journal: PLoS One Date: 2014-10-30 Impact factor: 3.240
Authors: N Najafi; G Hofer; P Gattinger; D Smiljkovic; K Blatt; R Selb; A Stoecklinger; W Keller; P Valent; V Niederberger; J Thalhamer; R Valenta; S Flicker Journal: Sci Rep Date: 2019-03-08 Impact factor: 4.379
Authors: Julia Eckl-Dorna; Sergio Villazala-Merino; Birgit Linhart; Alexander V Karaulov; Yury Zhernov; Musa Khaitov; Verena Niederberger-Leppin; Rudolf Valenta Journal: Front Immunol Date: 2019-01-17 Impact factor: 7.561